Indolapril

structure given in first source

Also Known As:

1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)alanyl)octahydro-1H-indole-2-carboxylic acid; CI 907; CI-907; Indolapril hydrochloride; PD 109,763-2; PD-109,763-2; Sch 31846; Sch-31846

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indolapril: 1

Experts

1.	Chen, Wansu: 1 article (01/2016)
2.	Dalal, Anand A: 1 article (01/2016)
3.	Kawatkar, Aniket A: 1 article (01/2016)
4.	Ngor, Eunice W: 1 article (01/2016)
5.	Qian, Lei: 1 article (01/2016)
6.	Schatz, Michael: 1 article (01/2016)
7.	Suruki, Robert Y: 1 article (01/2016)
8.	Zeiger, Robert S: 1 article (01/2016)

Related Diseases

1.	Asthma (Bronchial Asthma) 01/01/2016 - "The adjusted asthma-related average direct cost per patient at follow-up was significantly higher for SUA (mean ± SE) ($2325 ± $75) than non-SUA ($1261 ± $9) with an incremental cost of $1056 (95% CI, $907-$1205). "